The last time someone tried to rewrite the manual for peripheral nerve repair, surgeons were still using needles and hair-thin sutures. Today, Tissium wants to eliminate both from the operating room, at least for one specific type of injury. With a €60 million funding round, the Paris-based startup is preparing to introduce its proprietary system into the United States: a light-curable polymeric glue that bonds the two ends of a severed nerve without any suture.

The news marks a turning point for a technology that, on paper, promises to remove one of the most frustrating bottlenecks in microsurgery – the difficulty of manipulating millimeter-scale structures with absolute precision while reducing operating times and the risk of collateral damage. Yet, like any innovation stepping into a practice unchanged for decades, the path to mass adoption is paved with regulatory questions, cultural resistance, and the need to prove solid clinical results beyond Europe.

Why glue instead of suture

The technical gesture of suturing a nerve has remained essentially the same since the pioneers of reconstructive surgery developed the first techniques. The two frayed stumps are brought together, sutures are passed with ultra-fine threads under microscopic magnification, and one hopes axonal regeneration will follow. It’s a procedure that demands dexterity, time, and does not always prevent painful neuromas or fibrosis.

Tissium’s system bypasses the needle with a liquid tissue adhesive that, once applied to the junction, is polymerised in a few seconds by a light source at a specific wavelength. The material was designed to have mechanical properties compatible with nerve tissue: flexible, biodegradable over weeks, and capable of holding the ends aligned without compression. The company emphasises that it is the only device of its kind to have received FDA clearance, a stamp no competitor has managed to secure so far.

The journey from the lab to regulatory approval was not painless. Tissium had to convince authorities that the glue provided sufficient mechanical hold during the critical healing phase, without migrating or causing inflammation. The underlying platform – synthetic polymers functionalised with photoactive groups – stems from research conducted in French academic labs, later industrialised with a scalable manufacturing process. This materials science core is the real asset the startup intends to export across the Atlantic.

The US landing: a game of regulatory and commercial chess

The €60 million raised will not finance new research but will build the commercial and training infrastructure needed to enter American hospitals. This is not just about selling a device; it’s about convincing hand surgeons and neurosurgeons to replace a gesture they have performed automatically for years with a completely different procedure.

The challenge is typical for breakthrough medical devices: even if preclinical data and early European clinical studies suggest advantages in operating time and reduced complications, the surgical community remains cautious. In the United States, reimbursement systems and insurance pressures push toward technologies with a clear cost-effectiveness profile. Tissium will therefore have to bring not only a product but also packages of clinical evidence that justify the price, the learning curve, and any need to adapt surgical protocols.

The strategy seems to be focusing on specific indications – traumatic peripheral nerve injuries, such as those to fingers or the brachial plexus – where case numbers are high and the perceived benefit is immediate. The company speaks of “selling by teaching”: training centres of excellence that become ambassadors for the technology, generating real-world clinical data to fuel wider adoption.

What it means for the European medtech ecosystem

The Tissium story matters beyond the surgical suite. It’s a symptom of a European medical technology ecosystem that, after years of investment in basic research, is starting to produce companies capable of tackling the global market without necessarily sheltering under a large multinational. The fact that a device born in a French academic lab is now competing directly in the United States – the most demanding and profitable market in the world – signals a maturation of continental startups.

Of course, the path is full of pitfalls: volume production, polymer supply chain, intellectual property protection, and competition from companies offering biological alternatives such as collagen conduits or autologous nerve grafts. But the competitive edge of a “plug-and-play” system that requires no tissue harvesting and shortens operating room time could prove decisive, especially in a hospital environment increasingly focused on efficiency.

It remains to be seen whether the transition from innovative startup to solid commercial company will be managed without stumbles. Tens-of-millions funding rounds bring high expectations and the risk of leaving the validation phase too early. Yet, for those watching the industry from an industrial strategy perspective, Tissium is a test case: can a frontier technology, driven with regulatory discipline, truly scale from Paris to Palo Alto without losing its soul?